Mackay Shields LLC boosted its position in Agilent Technologies Inc (NYSE:A) by 473.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 296,305 shares of the medical research company’s stock after buying an additional 244,673 shares during the quarter. Mackay Shields LLC’s holdings in Agilent Technologies were worth $19,988,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. Findlay Park Partners LLP purchased a new position in Agilent Technologies in the fourth quarter worth approximately $246,229,000. Oregon Public Employees Retirement Fund raised its stake in shares of Agilent Technologies by 6,563.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,338,299 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 2,303,208 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Agilent Technologies by 170.0% in the third quarter. Marshall Wace LLP now owns 2,649,502 shares of the medical research company’s stock valued at $186,896,000 after acquiring an additional 1,668,360 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Agilent Technologies by 1,375.4% in the third quarter. Point72 Asset Management L.P. now owns 1,504,860 shares of the medical research company’s stock valued at $106,153,000 after acquiring an additional 1,402,860 shares in the last quarter. Finally, Pendal Group Ltd raised its stake in shares of Agilent Technologies by 17,076.7% in the fourth quarter. Pendal Group Ltd now owns 1,227,965 shares of the medical research company’s stock valued at $71,925,000 after acquiring an additional 1,220,816 shares in the last quarter.
In related news, CEO Michael R. Mcmullen sold 17,491 shares of the firm’s stock in a transaction dated Wednesday, January 30th. The stock was sold at an average price of $75.00, for a total transaction of $1,311,825.00. Following the transaction, the chief executive officer now owns 456,430 shares of the company’s stock, valued at $34,232,250. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Rodney Gonsalves sold 6,155 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $79.79, for a total value of $491,107.45. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,171 shares of company stock worth $5,764,185.
Shares of A traded up $0.56 during midday trading on Friday, reaching $81.17. 403,181 shares of the stock were exchanged, compared to its average volume of 1,939,267. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.79 and a current ratio of 3.39. Agilent Technologies Inc has a twelve month low of $60.42 and a twelve month high of $81.76. The stock has a market capitalization of $25.38 billion, a P/E ratio of 29.09, a price-to-earnings-growth ratio of 2.22 and a beta of 1.38.
Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.03. Agilent Technologies had a return on equity of 19.90% and a net margin of 22.86%. The business had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the firm earned $0.66 earnings per share. The business’s revenue was up 6.0% compared to the same quarter last year. On average, equities research analysts forecast that Agilent Technologies Inc will post 3.06 EPS for the current fiscal year.
Agilent Technologies announced that its Board of Directors has authorized a share buyback plan on Monday, November 19th that allows the company to repurchase $1.75 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 8.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2019/03/15/mackay-shields-llc-increases-position-in-agilent-technologies-inc-a.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Recommended Story: What is a Candlestick Chart?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.